ArticleFrontiers in oncology2024
Optimized FDG-PET/MRI protocol reveals metabolic predictors of long-term survival in pancreatic cancer patients.
Article in Frontiers in oncology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To optimize and assess an abbreviated dual time-point 18-Fluor-Deoxyglucose (FDG)-Positron Emission Tomography (PET)/Magnetic Resonance Imaging (MRI) protocol for predicting patient outcomes in pancreatic cancer. Methods: 70 patients (47 pancreatic cancer, 23 chronic pancreatitis) underwent hybrid PET/MRI with dual time-point PET/CT at 60 and 84 minutes post-injection. Metabolic indices (MI) were calculated from Standardized Uptake Value (SUV) changes (SUVmin, SUVmean and SUVmax). Multivariate analysis was performed on PET, MRI, laboratory, and histologic data. Top predictors were used for survival analysis. Results: MI SUVmax, thresholded at 11%, was the best outcome predictor, distinguishing high-risk (2year (2y)-Overall Survival (OAS) 32%, 5y-OAS 14%, 10y-OAS 8%) and low-risk groups (2y-OAS 76%, 5y-OAS 32%, 10y-OAS 23%). Tumor size, CBD obstruction, and infiltrative disease had lower predictive value. Conclusions: Metabolic indices from abbreviated dual time-point FDG-PET/MRI can differentiate pancreatic malignancy from pancreatitis and predict outcomes, outperforming other indices. This protocol offers a valuable diagnostic tool for characterizing pancreatic lesions and predicting outcomes based on imaging criteria.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.